Neoadjuvant Immunotherapy Delivers Near-Perfect 5-Year Survival in Melanoma Responders
A 1,038-patient international analysis finds 5-year overall survival exceeding 97% in melanoma patients who achieve a major pathological response to neoadjuvant checkpoint inhibitors.
Summary
This large international pooled analysis examined outcomes in 1,038 stage IIIB-D melanoma patients treated before surgery with immune checkpoint inhibitors (ICIs), targeted BRAF/MEK inhibitors, or combination therapy across 26 centers worldwide. Patients who achieved a major pathological response — meaning the tumor was largely destroyed before surgery — had extraordinary 5-year survival rates above 97–98%. Combination checkpoint immunotherapy (anti-PD-1 plus another immune agent) outperformed single-agent anti-PD-1 in response rates and survival. Targeted BRAF/MEK inhibitors alone performed poorly long-term. Remarkably, patients who responded fully to pre-surgical immunotherapy gained no additional benefit from continuing immune therapy after surgery, suggesting adjuvant treatment can be safely omitted in this group. The findings solidify neoadjuvant immunotherapy as the standard of care for resectable advanced melanoma and highlight the urgent need for better strategies in non-responders.
Detailed Summary
Melanoma treated at an advanced but still-resectable stage is a critical window where the sequence and type of therapy can profoundly shape long-term survival. Neoadjuvant immunotherapy — giving immune checkpoint inhibitors before surgery to shrink tumors and prime systemic immunity — has emerged as a promising strategy, but long-term survival data and guidance on post-surgical management have been lacking. This updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC) provides the most comprehensive five-year outcome data to date.
Researchers analyzed 1,038 patients with resectable stage IIIB-D melanoma treated at 26 international centers, including both trial and real-world settings. Patients received neoadjuvant ICIs (n=735), BRAF and MEK inhibitors (n=119), or ICIs combined with targeted therapy (n=184). ICI regimens were further divided into anti-PD-1 alone versus anti-PD-1 combined with additional immunotherapy agents.
The results were striking. Among ICI-treated patients achieving a major pathological response — defined as near-complete or complete tumor destruction — five-year overall survival reached 98.8% with single-agent anti-PD-1 and 97.9% with combination immunotherapy, figures rarely seen in metastatic solid tumors. Combination immunotherapy (PD-1 plus additional IO agent) produced higher major pathological response rates (61.4% vs. 49.5%) and better five-year recurrence-free survival (73.9% vs. 61.0%) than single-agent anti-PD-1. In sharp contrast, BRAF/MEK inhibitor-treated patients had a five-year overall survival of only 69.8%, and combination ICI plus targeted therapy yielded mixed results.
A clinically important finding was that patients achieving major pathological response derived no benefit from continuing immunotherapy into the adjuvant (post-surgical) phase, raising the possibility of de-escalating treatment in this group and sparing them toxicity. Neoadjuvant ICIs also showed activity across challenging subgroups including BRAF-mutant, acral, in-transit, and oligometastatic melanoma.
Caveats include that this summary is based on the abstract only and full methodology is unavailable. The analysis is pooled and observational in part, with multiple competing interests among authors. Subgroup sizes were variable, limiting conclusions in rarer melanoma types. Future biomarker-driven trials are needed to identify and rescue non-responders.
Key Findings
- Melanoma patients achieving major pathological response to neoadjuvant ICIs had 5-year overall survival of 97–99%.
- Combination anti-PD-1 plus additional immunotherapy outperformed single-agent anti-PD-1 in response rates and 5-year survival.
- BRAF/MEK inhibitor neoadjuvant therapy yielded only 69.8% 5-year overall survival, far below ICI regimens.
- Major responders to neoadjuvant ICIs gained no benefit from continuing immunotherapy after surgery.
- Neoadjuvant ICIs showed activity in BRAF-mutant, acral, in-transit, and oligometastatic melanoma subgroups.
Methodology
Pooled retrospective and prospective analysis of 1,038 patients from 26 international sites, including both clinical trial (72.7%) and real-world (27.3%) cohorts. Endpoints included major pathological response, recurrence-free survival, and overall survival at five years. Treatment arms were not randomized across the full dataset, introducing selection bias.
Study Limitations
The pooled design mixes trial (72.7%) and real-world (27.3%) patients across 26 international sites and was not fully randomized, limiting causal inference regarding treatment comparisons. Subgroup analyses — particularly for acral, in-transit, and oligometastatic melanoma — were limited by small sample sizes. Numerous authors report extensive pharmaceutical industry relationships, which should be considered when interpreting conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: